Table I.

Interpretation of susceptibility pattern of rapidly growing mycobacteria according to the CLSI recommendations.

Antimycobacterial agents	MIC breakpoints (μg/ml)
	S	I	R
Amikacin	≤ 16	32	≥ 64
Cefoxitin	≤ 16	32-64	≥ 128
Doxycycline	≤ 1	2-4	≥ 32
Ciprofloxacin	≤ 1	2	≥ 4
Clarithromycin	≤ 2	4	≥ 8
Linezolid	≤ 8	16	≥ 32
Moxifloxacin	≤ 1	2	≥ 4
Trimthoprim/sulfamethoazole	≤ 2/38	–	≥ 4/76
Imipenem	≤ 4	8-16	≥ 32
Tigecycline*	–	–	–

¹S – susceptible, I – intermediate, R – resistant

¹* – insufficient data on tigecycline’s correlation between in vitro results and clinical response hinders the establishment of breakpoints to differentiate susceptible from resistant strain, thus only MIC should be reported